US20030176357A1
(en)
*
|
1998-10-06 |
2003-09-18 |
Pospisilik Andrew J. |
Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
|
TWI249401B
(en)
*
|
1999-04-14 |
2006-02-21 |
Takeda Chemical Industries Ltd |
Agent for improving ketosis
|
PE20020323A1
(es)
*
|
2000-08-22 |
2002-06-13 |
Novartis Ag |
COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
US7144862B2
(en)
*
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
US7723303B2
(en)
*
|
2000-08-24 |
2010-05-25 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
US7199102B2
(en)
*
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
US7166578B2
(en)
|
2000-08-24 |
2007-01-23 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
US7148197B2
(en)
*
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
JP4605990B2
(ja)
*
|
2000-12-21 |
2011-01-05 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
新規な1,2−ジフェニルアゼチジノン、その調製方法、その化合物を含む薬剤、および脂質代謝障害を治療するためのその使用
|
US7025985B2
(en)
*
|
2001-05-28 |
2006-04-11 |
Kanebo, Ltd. |
Dihydroxyphenyl compounds and glucoside compounds thereof
|
CN1512878A
(zh)
*
|
2001-05-28 |
2004-07-14 |
钟纺株式会社 |
脂肪分解促进剂及含有该成分的皮肤化妆原料、饮食品合成物及瘦身方法和用途
|
US6987123B2
(en)
|
2001-07-26 |
2006-01-17 |
Cadila Healthcare Limited |
Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
|
AU2002336532C1
(en)
|
2001-09-14 |
2008-10-16 |
Amgen, Inc |
Linked biaryl compounds
|
US20030220374A1
(en)
*
|
2002-01-14 |
2003-11-27 |
Pharmacia Corporation |
Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
|
AR039090A1
(es)
*
|
2002-03-22 |
2005-02-09 |
Novartis Ag |
Combinacion de compuestos organicos
|
US6716842B2
(en)
|
2002-04-05 |
2004-04-06 |
Warner-Lambert Company, Llc |
Antidiabetic agents
|
WO2003088962A1
(en)
*
|
2002-04-16 |
2003-10-30 |
Merck & Co., Inc. |
Combination therapy using a ppar alpha/gamma agonist
|
ITMI20021012A1
(it)
*
|
2002-05-13 |
2003-11-13 |
Giovanni Scaramuzzino |
Combinazione di un inibitore dell'enzima hmg-coa reduttasi e di un estere nitrato
|
EP1388352A1
(en)
*
|
2002-08-08 |
2004-02-11 |
Laboratoires Fournier S.A. |
Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
|
BR0313825A
(pt)
|
2002-08-29 |
2005-07-12 |
Merck & Co Inc |
Composto, composição farmacêutica, método para tratar de diabete mellitus tipo 2 em um mamìfero, e, uso de composto
|
AU2003260085B2
(en)
*
|
2002-08-29 |
2008-09-11 |
Merck & Co., Inc. |
Indoles having anti-diabetic activity
|
ATE345340T1
(de)
|
2002-09-12 |
2006-12-15 |
Hoffmann La Roche |
N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis
|
DE10300099A1
(de)
*
|
2003-01-07 |
2004-07-15 |
Bayer Healthcare Ag |
Indol-Phenylsulfonamid-Derivate
|
GEP20084540B
(en)
|
2003-01-14 |
2008-11-25 |
Arena Pharm Inc |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
CA2513102C
(en)
|
2003-01-27 |
2011-03-22 |
Merck & Co., Inc. |
Substituted pyrazoles, compositions containing such compounds and methods of use
|
JP2006524248A
(ja)
*
|
2003-04-14 |
2006-10-26 |
ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー |
糖尿病の治療用のn−(((((1,3−チアゾール−2−イル)アミノ)カルボニル)フェニル)スルホニル)フェニルアラニン誘導体及び関連化合物
|
KR20060006953A
(ko)
|
2003-04-30 |
2006-01-20 |
디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 |
치환된 카르복실산
|
US7981915B2
(en)
*
|
2003-04-30 |
2011-07-19 |
Beth Israel Deaconess Medical Center |
Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
|
WO2004098510A2
(en)
*
|
2003-04-30 |
2004-11-18 |
Beth Israel Deaconess Medical Center |
Cystic fibrosis therapy
|
WO2004100895A2
(en)
*
|
2003-05-13 |
2004-11-25 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
|
US7601756B2
(en)
*
|
2003-06-06 |
2009-10-13 |
Snowden Pharmaceuticals, Llc |
Method of treatment for irritable bowel syndrome
|
EP1635773A2
(en)
*
|
2003-06-06 |
2006-03-22 |
Merck & Co., Inc. (a New Jersey corp.) |
Combination therapy for the treatment of hypertension
|
KR20060056944A
(ko)
|
2003-07-14 |
2006-05-25 |
아레나 파마슈티칼스, 인크. |
대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
|
DE10335449A1
(de)
*
|
2003-08-02 |
2005-02-17 |
Bayer Healthcare Ag |
Bicyclische Indolinsulfonamid-Derivate
|
DE10337839A1
(de)
*
|
2003-08-18 |
2005-03-17 |
Bayer Healthcare Ag |
Indolin-Derivate
|
US20050074443A1
(en)
*
|
2003-10-03 |
2005-04-07 |
Treadwell Benjamin V. |
Methods of attenuating autoimmune disease and compositions useful therefor
|
KR100849352B1
(ko)
|
2003-11-05 |
2008-07-29 |
에프. 호프만-라 로슈 아게 |
Ppar 활성화제로서 벤조-융합된 화합물
|
RU2374230C2
(ru)
|
2003-11-05 |
2009-11-27 |
Ф.Хоффманн-Ля Рош Аг |
Фенильные производные в качестве ppar агонистов
|
MXPA06004642A
(es)
|
2003-11-05 |
2006-06-27 |
Hoffmann La Roche |
Derivados de heteroaril como activadores de los receptores activados de proliferadores de peroxisoma (ppar).
|
EP1689389A4
(en)
|
2003-12-04 |
2009-06-17 |
Nat Health Research Institutes |
Indole compounds
|
TWI297606B
(en)
*
|
2004-01-16 |
2008-06-11 |
Nat Health Research Institutes |
Cancer therapy
|
JP2007534702A
(ja)
*
|
2004-04-26 |
2007-11-29 |
バンダービルト・ユニバーシティ |
胃腸毒性の低い治療薬としてのインドール酢酸、及びインデン酢酸誘導体
|
US20080076810A1
(en)
*
|
2004-05-28 |
2008-03-27 |
Weiguo Lui |
Benzoureas Having Anti-Diabetic Activity
|
CA2568766A1
(en)
*
|
2004-05-29 |
2005-12-08 |
7Tm Pharma A/S |
Crth2 receptor ligands for medicinal uses
|
PL1756064T3
(pl)
*
|
2004-06-04 |
2008-11-28 |
Merck Sharp & Dohme |
Pochodne pirazolu, kompozycje zawierające takie związki oraz sposoby ich zastosowania
|
CA2571789A1
(en)
|
2004-07-02 |
2006-02-09 |
Merck & Co., Inc. |
Indoles having anti-diabetic activity
|
EP1773330B1
(en)
|
2004-07-22 |
2010-05-26 |
Merck Sharp & Dohme Corp. |
Substituted pyrazoles, compositions containing such compounds and methods of use
|
NZ552878A
(en)
|
2004-07-30 |
2010-01-29 |
Salvat Lab Sa |
Tyrosine derivatives as PPAR-gamma-modulators
|
CA2580501A1
(en)
*
|
2004-09-16 |
2006-03-30 |
The Regents Of The University Of California |
G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
|
US20060122222A1
(en)
*
|
2004-11-18 |
2006-06-08 |
The Institutes For Pharmaceutical Discovery, Llc |
Heterocycle substituted carboxylic acids
|
WO2006063132A2
(en)
|
2004-12-06 |
2006-06-15 |
The Regents Of The University Of California |
Methods for improving the structure and function of arterioles
|
DOP2006000008A
(es)
*
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
JP4638512B2
(ja)
|
2005-03-04 |
2011-02-23 |
メルク・シャープ・エンド・ドーム・コーポレイション |
抗糖尿病活性を有する縮合芳香族化合物
|
US20080293639A1
(en)
*
|
2005-04-29 |
2008-11-27 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
AU2006242651B2
(en)
*
|
2005-04-29 |
2013-05-16 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
ES2375302T3
(es)
*
|
2005-05-24 |
2012-02-28 |
Dsm Ip Assets B.V. |
Derivados de ligustilida para el tratamiento de trastornos inflamatorios.
|
AU2006269503A1
(en)
|
2005-07-06 |
2007-01-18 |
Merck & Co., Inc. |
Antidiabetic oxazolidinediones and thiazolidinediones
|
JP2009502923A
(ja)
|
2005-07-26 |
2009-01-29 |
メルク エンド カムパニー インコーポレーテッド |
置換ピラゾールを合成するための方法
|
US20070161006A1
(en)
*
|
2006-01-10 |
2007-07-12 |
Vita Genomics, Inc. |
Single nucleotide polymorphisms in protein-tyrosine phosphatase receptor-type delta for the diagnosis of susceptibility to infection and asthma
|
ES2354390T3
(es)
*
|
2006-04-11 |
2011-03-14 |
Arena Pharmaceuticals, Inc. |
Procedimientos de uso del receptor gpr119 para identificar compuestos útiles para aumentar la masa ósea en un individuo.
|
PE20071221A1
(es)
*
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
CA2657691A1
(en)
|
2006-06-19 |
2007-12-27 |
Vanderbilt University |
Methods and compositions for diagnostic and therapeutic targeting of cox-2
|
JP2010502719A
(ja)
|
2006-09-08 |
2010-01-28 |
ロード アイランド ホスピタル |
アルコール誘発性脳疾患の治療、予防および回復
|
CN102317296B
(zh)
|
2007-01-26 |
2015-05-27 |
卡内克制药公司 |
稠合芳烃ptp-1b抑制剂
|
WO2008104055A1
(en)
*
|
2007-02-26 |
2008-09-04 |
Merck Frosst Canada Ltd. |
Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
|
WO2008137105A1
(en)
|
2007-05-07 |
2008-11-13 |
Merck & Co., Inc. |
Method of treatment using fused aromatic compounds having anti-diabetic activity
|
US20080319218A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Andreas Haubrich |
Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
|
US20080319221A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
WO2009032693A2
(en)
|
2007-08-28 |
2009-03-12 |
Uab Research Foundation |
Synthetic apolipoprotein e mimicking polypeptides and methods of use
|
US8557767B2
(en)
|
2007-08-28 |
2013-10-15 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
FR2921366B1
(fr)
*
|
2007-09-26 |
2009-12-04 |
Servier Lab |
Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
DE102007054497B3
(de)
*
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
EP2146210A1
(en)
*
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
WO2010056717A1
(en)
|
2008-11-17 |
2010-05-20 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
TW201028414A
(en)
|
2009-01-16 |
2010-08-01 |
Merck Sharp & Dohme |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
EP2389368B1
(en)
|
2009-01-23 |
2015-06-17 |
Merck Sharp & Dohme Corp. |
Bridged and fused antidiabetic compounds
|
US20110312995A1
(en)
|
2009-01-23 |
2011-12-22 |
Schering Corporation |
Bridged and fused heterocyclic antidiabetic compounds
|
EP2393810A1
(en)
|
2009-02-05 |
2011-12-14 |
Schering Corporation |
Phthalazine-containing antidiabetic compounds
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
CA2768577A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
US8552022B2
(en)
|
2009-08-13 |
2013-10-08 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
KR20120092096A
(ko)
|
2009-09-02 |
2012-08-20 |
머크 샤프 앤드 돔 코포레이션 |
당뇨병의 치료 또는 예방을 위한 디펩티딜 펩티다제-iv 억제제로서의 아미노테트라히드로피란
|
JP2013517272A
(ja)
|
2010-01-15 |
2013-05-16 |
メルク・シャープ・エンド・ドーム・コーポレイション |
抗糖尿病化合物としてのオキサジアゾール・ベータ・カルボリン誘導体
|
US8853212B2
(en)
|
2010-02-22 |
2014-10-07 |
Merck Sharp & Dohme Corp |
Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
|
WO2011137024A1
(en)
|
2010-04-26 |
2011-11-03 |
Merck Sharp & Dohme Corp. |
Novel spiropiperidine prolylcarboxypeptidase inhibitors
|
WO2011143057A1
(en)
|
2010-05-11 |
2011-11-17 |
Merck Sharp & Dohme Corp. |
Novel prolylcarboxypeptidase inhibitors
|
US8980929B2
(en)
|
2010-05-21 |
2015-03-17 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
EP2579873A4
(en)
|
2010-06-11 |
2013-11-27 |
Merck Sharp & Dohme |
NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
|
EP2605658B1
(en)
|
2010-08-18 |
2016-03-23 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
CN103221410B
(zh)
|
2010-09-22 |
2017-09-15 |
艾尼纳制药公司 |
Gpr119受体调节剂和对与其相关的障碍的治疗
|
JP2013540817A
(ja)
|
2010-10-29 |
2013-11-07 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ジアゼニウムジオレート複素環誘導体
|
US8933113B2
(en)
|
2011-01-20 |
2015-01-13 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
JO3350B1
(ar)
|
2011-03-07 |
2019-03-13 |
Merck Sharp & Dohme |
مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
|
WO2012138845A1
(en)
|
2011-04-08 |
2012-10-11 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
WO2012139495A1
(en)
|
2011-04-13 |
2012-10-18 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
US9272987B2
(en)
|
2011-05-02 |
2016-03-01 |
Merck Sharp & Dohme Corp. |
Diazeniumdiolate cyclohexyl derivatives
|
EP2714678A1
(en)
|
2011-06-02 |
2014-04-09 |
Intervet International B.V. |
Imidazole derivatives
|
EP2720544B1
(en)
|
2011-06-16 |
2016-12-21 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
|
WO2012178142A1
(en)
*
|
2011-06-23 |
2012-12-27 |
Metabolic Solutions Development Company, Llc |
Ppar-sparing compounds and combinations fort the treatment of diabetes and other metabolic diseases
|
WO2013048916A1
(en)
|
2011-09-30 |
2013-04-04 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
EP2765859B1
(en)
|
2011-10-13 |
2017-01-18 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
WO2013059245A1
(en)
|
2011-10-17 |
2013-04-25 |
Vanderbilt University |
Indomethacin analogs for the treatment of castrate-resistant prostate cancer
|
EP2771000B1
(en)
|
2011-10-24 |
2016-05-04 |
Merck Sharp & Dohme Corp. |
Substituted piperidinyl compounds useful as gpr119 agonists
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
WO2013068328A1
(en)
|
2011-11-07 |
2013-05-16 |
Intervet International B.V. |
Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
|
WO2013068439A1
(en)
|
2011-11-09 |
2013-05-16 |
Intervet International B.V. |
4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
|
EP2780337B1
(en)
|
2011-11-15 |
2017-12-20 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as gpr119 agonists
|
WO2013122920A1
(en)
|
2012-02-17 |
2013-08-22 |
Merck Sharp & Dohme Corp. |
Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
|
WO2013155600A1
(en)
|
2012-04-16 |
2013-10-24 |
Kaneq Pharma |
Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
|
US9315508B2
(en)
|
2012-07-23 |
2016-04-19 |
Merck Sharp & Dohme Corp. |
Treating diabetes with dipeptidyl peptidase-IV inhibitors
|
EP2931734B1
(en)
|
2012-12-17 |
2020-12-02 |
Merck Sharp & Dohme Corp. |
Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment
|
EP2934518B1
(en)
|
2012-12-19 |
2020-02-19 |
Merck Sharp & Dohme Corp. |
Spirocyclic cetp inhibitors
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
EP3097101B1
(en)
|
2014-01-24 |
2020-12-23 |
Merck Sharp & Dohme Corp. |
Isoquinoline derivatives as mgat2 inhibitors
|
US10011572B2
(en)
|
2014-07-29 |
2018-07-03 |
Merck Sharp & Dohme Corp. |
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
IL250302B
(en)
|
2014-07-31 |
2022-07-01 |
Uab Research Foundation |
Apoe mimetic peptides with high potency to clear plasma cholesterol
|
US10100042B2
(en)
|
2014-08-08 |
2018-10-16 |
Merck Sharp & Dohme Corp. |
[5,6]—fused bicyclic antidiabetic compounds
|
US10662171B2
(en)
|
2014-08-08 |
2020-05-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10968193B2
(en)
|
2014-08-08 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
AU2015335828B2
(en)
|
2014-10-24 |
2018-08-23 |
Merck Sharp & Dohme Llc |
Co-agonists of the glucagon and GLP-1 receptors
|
TW201625635A
(zh)
|
2014-11-21 |
2016-07-16 |
默沙東藥廠 |
作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
|
NZ734220A
(en)
|
2015-01-06 |
2022-01-28 |
Arena Pharm Inc |
Methods of treating conditions related to the s1p1 receptor
|
US10245264B2
(en)
|
2015-05-27 |
2019-04-02 |
Merck Sharp & Dohme Corp. |
Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators
|
WO2016191335A1
(en)
|
2015-05-28 |
2016-12-01 |
Merck Sharp & Dohme Corp. |
Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
|
IL285890B
(en)
|
2015-06-22 |
2022-07-01 |
Arena Pharm Inc |
Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
|
WO2017011279A1
(en)
|
2015-07-13 |
2017-01-19 |
Merck Sharp & Dohme Corp. |
Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
|
US10800826B2
(en)
|
2015-10-05 |
2020-10-13 |
Merck Sharp & Dohme Corp. |
Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
|
US10450309B2
(en)
|
2015-11-30 |
2019-10-22 |
Merch Sharp & Dohme Corp. |
Aryl sulfonamides as BLT1 antagonists
|
EP3383868B1
(en)
|
2015-11-30 |
2022-10-05 |
Merck Sharp & Dohme LLC |
Aryl sulfonamides as blt1 antagonists
|
WO2017107052A1
(en)
|
2015-12-22 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase stimulators
|
WO2017197555A1
(en)
|
2016-05-16 |
2017-11-23 |
Merck Sharp & Dohme Corp. |
Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
|
WO2017201683A1
(en)
|
2016-05-25 |
2017-11-30 |
Merck Sharp & Dohme Corp. |
Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
|
US10414775B2
(en)
|
2016-08-15 |
2019-09-17 |
Merck Sharp & Dohme Corp. |
Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
|
EP3496716B1
(en)
|
2016-08-15 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
|
WO2018057409A1
(en)
|
2016-09-20 |
2018-03-29 |
Merck Sharp & Dohme Corp. |
Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as pcsk9 allosteric binders
|
AU2017360941A1
(en)
|
2016-11-18 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Indole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
|
WO2018107415A1
(en)
|
2016-12-15 |
2018-06-21 |
Merck Sharp & Dohme Corp. |
Hydroxy isoxazole compounds useful as gpr120 agonists
|
JP2020507611A
(ja)
|
2017-02-16 |
2020-03-12 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
原発性胆汁性胆管炎の治療のための化合物および方法
|
JOP20190150A1
(ar)
|
2018-06-21 |
2019-12-21 |
Merck Sharp & Dohme |
مركبات مناهضة لـ pcsk9
|
WO2020205688A1
(en)
|
2019-04-04 |
2020-10-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
US20220273669A1
(en)
|
2019-05-22 |
2022-09-01 |
Merck Sharp Dohme Corp. |
Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
|
US20220281886A1
(en)
|
2019-05-22 |
2022-09-08 |
Merck Sharp Dohme Corp. |
Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
|
EP4021919A1
(en)
|
2019-08-30 |
2022-07-06 |
Merck Sharp & Dohme Corp. |
Pcsk9 antagonist compounds
|
EP3842061A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled triazole co-agonists of the glucagon and glp-1 receptors
|
EP3842060A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled lactam co-agonists of the glucagon and glp-1 receptors
|
EP3842449A1
(en)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Stapled olefin co-agonists of the glucagon and glp-1 receptors
|
WO2021236401A1
(en)
|
2020-05-18 |
2021-11-25 |
Merck Sharp & Dohme Corp. |
Novel diacylglyceride o-acyltransferase 2 inhibitors
|
AU2022330007A1
(en)
|
2021-08-19 |
2024-02-15 |
Merck Sharp & Dohme Llc |
Compounds for treating conditions related to pcsk9 activity
|
WO2023244554A1
(en)
|
2022-06-15 |
2023-12-21 |
Merck Sharp & Dohme Llc |
Cyclic peptides for trapping interleukin-1 beta
|